ATS 2020 Advance Program

leading cause of death during the initial year after transplantation. Allogeneic HCTs are associated with more severe pulmonary complications such as pneumonitis (infectious and non-infectious) and pulmonary hemorrhage during the first year after transplant. Predictors of these life-threatening conditions are unknown. A recent NIH workshop explored the etiology of lung injury occurring within a year after HCT in children, to identify critical gaps in existing knowledge, and to explore avenues for research to address these knowledge gaps to advance care and optimize outcomes. Chairing: S.B. Goldfarb, MD, ATSF, Philadelphia, PA A. Natarajan, MD, PhD, Bethesda, MD 9:15 Update Pulmonary Complications of Pediatric Hematopoietic Stem Cell Transplantation (HCT) Current Landscape and Future Research Directions S.B. Goldfarb, MD, ATSF, Philadelphia, PA 9:20 Overview of Indications for Hematopoietic Stem Cell Transplants and Early and Late Pulmonary Complications W.A. Gower, MD, MS, Chapel Hill, NC 9:35 Early Lung Injury Post Hematopoietic Stem Cell Transplantation S. Davies, MBBS, PhD, Cincinnati, OH 9:55 Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation S. Paczesny, MD, PhD, Indianapolis, IN 10:15 Advances in Understanding Pulmonary Infections after Hematopoietic Cell Transplantation M. Zinter, MD, San Francisco, CA 10:35 Pathways to Fibrosis: Viral Infections and Animal Models B.B. Moore, PhD, ATSF, Ann Arbor, MI 10:55 Imaging and Early Detection of Lung Injury Post Hematopoietic Stem Cell Transplantation J.C. Woods, PhD, Cincinnati, OH BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM B11 BEYOND DNA: THE UNSEEN GENOME AND NOVEL OMICS APPROACHES TO PULMONARY HYPERTENSION Assembly on Pulmonary Circulation; Section on Genetics and Genomics 9:15 a.m. - 11:15 a.m. Target Audience Researchers, nurses and physicians interested in learning how state of the art omics are used in lung disease research and translation to the clinic. Objectives At the conclusion of this session, the participant will be able to: • understand the role of long non-coding RNAs in Pulmonary Hypertension and learn about emerging therapeutic strategies targeting long non-coding RNAs with directions for future research and translational focus; • describe how single-cell technologies provide more detailed biological insight than traditional analysis of mixed cell populations; • understand how dysregulated metabolism contributes to pulmonary hypertension and identifies new therapeutic approaches. The development of powerful new omics tools is providing unprecedented insight into the pathobiology of lung disease, opening up new approaches for diagnosis, prognosis and therapy. Advances in RNA-sequencing techniques have led to the discovery of thousands of non-coding transcripts, including long non-coding RNAs (lncRNA) and microRNAs (miRNA) that are regulated during lung development and disease. This symposium explores the latest technological developments, including state of the art single cell technologies, proteomics and metabolomics, and highlights current knowledge of the function of non-coding RNAs in pulmonary vascular disease and right heart failure. ATS 2020 • Philadelphia, PA MONDAY • MAY 18 73